BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan B, Zhao X, Wang X, Liu E, Liu C, Zong Y, Jiang Y, Hou M, Chen Y, Chen L, Zhang Y, Wang H, Fu J. Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening. Clinical & Translational Med 2022;12. [DOI: 10.1002/ctm2.678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Wu C, Zhang S, Yu P, Li L, Guo C, Li R. A novel deep learning segmentation model for organoid-based drug screening. Front Pharmacol 2022;13:1080273. [PMID: 36588731 DOI: 10.3389/fphar.2022.1080273] [Reference Citation Analysis]
2 Wang E, Xiang K, Zhang Y, Wang X. Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models. Journal of the National Cancer Center 2022. [DOI: 10.1016/j.jncc.2022.10.001] [Reference Citation Analysis]
3 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022;71:1669-83. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Shiihara M, Furukawa T. Application of Patient-Derived Cancer Organoids to Personalized Medicine. JPM 2022;12:789. [DOI: 10.3390/jpm12050789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]